Abstract
Hepatocellular carcinoma (HCC) is a malignancy originating from liver cells. Hepatitis B virus (HBV) is the major etiological factor contributed to the development of HCC in China. Pathologically, HCC is usually characterized of hypervascularity. The rationale of transarterial chemoembolization (TACE) is that the intraarterial infusion of cytotoxic agents followed by embolization of the tumor-feeding blood vessels causes a strong tumor killing effect. TACE is the most widely used primary treatment for unresectable HCC. In 2018, Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma were published by Chinese College of Interventionalists. After several clinical and scientific advances are achieved, a new version of practice guidelines is updated in 2021.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
